Evidence map›Paper›PMID 26200312›Full record

ArticleCell reports2015

Uncovering a Role for SK2 in Angelman Syndrome.

Sofia B Lizarraga, Eric M Morrow

Open access · goldAbstract readComment
PubMed Publisher
In one paragraph

Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Sofia B LizarragaDepartment of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA; Center for Childhood Neurotherapeutics, University of South Carolina, Columbia SC 29208, USA. Electronic address: lizarras@mailbox.sc.edu.
Eric M MorrowDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown Institute for Brain Science and Laboratories for Molecular Medicine, Brown University, 70 Ship Street, Providence, RI 02912, USA; Developmental Disorders Genetics Research Program, Emma Pendleton Bradley Hospital, 1011 Veterans Memorial Parkway, East Providence, RI 02912, USA; Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University, Providence, RI 02912, USA. Electronic address: eric_morrow@brown.edu.
Brown Institute for Media Innovation · USUniversity of South Carolina · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angelman syndrome is a severe neurodevelopmental disorder caused by mutations in UBE3A. Sun et al. (2015) report SK2 as a UBE3A substrate and provide insight into the molecular mechanisms that might underlie impaired neuronal function in individuals affected by Angelman syndrome.

Indexed as

AnimalsLearningMaleMemoryNeuronal PlasticitySmall-Conductance Calcium-Activated Potassium ChannelsUbiquitin-Protein LigasesSmall-Conductance Calcium-Activated Potassium ChannelsUbiquitin-Protein Ligases

Identifiers

PMID26200312
OpenAlexW1489514857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.